Austin D. Kim - 06 Jan 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role: EVP & General Counsel
Signature: /s/ Austin D. Kim
Issuer symbol: ACAD
Transactions as of: 06 Jan 2022
Net transactions value: -$13,231
Form type: 4
Filing time: 10 Jan 2022, 17:24:45 UTC
Next filing: 25 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACAD	Common Stock	Options Exercise		+1,633	+13%		13,774	06 Jan 2022	Direct	F1, F2
transaction	ACAD	Common Stock	Sale	$13,231	-574	-4.2%	$23.05	13,200	06 Jan 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACAD	Restricted Stock Units	Options Exercise	$0	-1,633	-33%	$0.000000	3,267	06 Jan 2022	Common Stock	1,633		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	Includes 365 shares of the Issuer's common stock acquired by the reporting person on May 15, 2021 and 405 shares acquired by the reporting person on November 15, 2021, pursuant to an employee stock purchase program.
F3	The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F4	The restricted stock units vest in four equal annual installments beginning January 6, 2021.